A. Z. Mykytyn

This study compares the antigenic differences between SARS-CoV-2 Omicron BA.1 and BA.2 variants using antigenic cartography and hamster sera, finding they are distinct antigenic outliers.

This study compares the replication efficiency of SARS-CoV-2 Omicron with earlier variants in human airway and alveolar epithelial cells, finding higher replication in airways and reduced replication in alveolar type 2 cells.

This study shows that glycosylated mucin domains on respiratory epithelial cells restrict SARS-CoV-2 infection by reducing viral entry.

The paper assesses the replicative fitness of SARS-CoV-2 B.1.1.7 variant in human organoid models and finds higher infectious virus production and fitness compared to an ancestral strain.

The paper shows that using human airway cells prevents SARS-CoV-2 from mutating its multibasic cleavage site during propagation.

This paper develops a two-component spike nanoparticle vaccine that protects macaques from SARS-CoV-2 infection by inducing strong neutralizing antibodies and reducing viral replication.

This study shows that the SARS-CoV-2 spike protein's multibasic cleavage site enhances entry into human airway cells via serine proteases, and that blocking these proteases inhibits infection.

This study shows rabbits can be infected with SARS-CoV-2 and shed infectious virus from the nose and throat.

The paper shows SARS-CoV-2 infects human gut enterocytes in small intestinal organoids, leading to viral replication and a strong immune response.